 | • レポートコード：MRC2303I0165 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界のシリンジ市場規模が、予測期間中（2022年-2027年）に年平均10.1%で成長すると予測しています。本書では、シリンジの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、種類別（滅菌可能/再利用可能、使い捨て、従来型、安全注射器、プレフィルド）分析、用途別（インスリン、ボトックス、変形性関節症、ヒト成長ホルモン、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ、アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、その他）分析、競争状況、市場機会・将来の動向など、以下の構成でまとめております。また、Becton Dickinson and Company.、B. Braun Melsungen AG、Gerresheimer AG、Hindustan Syringes & Medical Devices Limited、Terumo Corporation、Nipro Corporation、Schott AG、Cardinal Health Inc.、Smiths Medical、Johnson & Johnsonなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のシリンジ市場規模：種類別 - 滅菌可能/再利用可能式シリンジの市場規模 - 使い捨て式シリンジの市場規模 - 従来式シリンジの市場規模 - 安全注射器シリンジの市場規模 - プレフィルド式シリンジの市場規模 ・世界のシリンジ市場規模：用途別 - インスリン注射用シリンジの市場規模 - ボトックス注射用シリンジの市場規模 - 変形性関節症注射用シリンジの市場規模 - ヒト成長ホルモン注射用シリンジの市場規模 - その他用途の市場規模 ・世界のシリンジ市場規模：地域別 - 北米のシリンジ市場規模 アメリカのシリンジ市場規模 カナダのシリンジ市場規模 メキシコのシリンジ市場規模 … - ヨーロッパのシリンジ市場規模 ドイツのシリンジ市場規模 イギリスのシリンジ市場規模 フランスのシリンジ市場規模 … - アジア太平洋のシリンジ市場規模 中国のシリンジ市場規模 インドのシリンジ市場規模 日本のシリンジ市場規模 … - 中東・アフリカのシリンジ市場規模 GCC諸国のシリンジ市場規模 南アフリカのシリンジ市場規模 … - 南米のシリンジ市場規模 ブラジルのシリンジ市場規模 アルゼンチンのシリンジ市場規模 … - その他地域のシリンジ市場規模 ・競争状況 ・市場機会・将来の動向 |
The syringe market is expected to register a CAGR of 10.1% during the forecast period, 2022-2027.
Due to COVID-19, a rise in the development of COVID-19 vaccines has been observed, which has led to an increased demand for syringes. For instance, in January 2020, the Biomedical Advanced Research and Development Authority (BARDA) estimated that between 650 million to 850 million needles and syringes were needed to administer a vaccine in the United States alone. As a result, the demand for syringes increased, which boosted the market’s growth. Hence, COVID-19 has a significant impact on the growth of the syringe market.
Furthermore, the major factors driving the growth of the syringe market include the growing prevalence of chronic and infectious diseases. As per the International Diabetes Federation 2021 report, the number of people living with diabetes was around 537 million (20-79 years) in the year 2021. Additionally, the number of people living with diabetes is expected to increase from 643 million in 2030 to nearly 783 million by 2045. Most of the diagnostic and therapeutic techniques for chronic diseases require syringes, as these play a vital role during tests and drug administration, and thus the growing burden of diseases is expected to drive the growth of the market.
Moreover, the increased adoption of injectable drugs, technological advancements in syringes, the increase in the geriatric population, and the growing number of vaccination and immunization programs are expected to drive the volume growth over the next few years. According to the World Health Organization 2021, in 2020, there were 727 million people aged 65 and above across the world. Between 2020 and 2050, the number of elderly people will grow in all regions. The proportion of the global population aged 65 and up is predicted to rise from 9.3% in 2020 to roughly 16.0 % in 2050. Moreover, by 2050, approximately 1 in 6 people globally will be over the age of 65. As the geriatric population is at high risk of various chronic diseases, with the increase in the geriatric population, the need for syringes is also expected to increase, and hence the market is expected to project growth over the coming years.
Additionally, in January 2022, Nephron Pharmaceuticals Corporation launched the cyclic olefin copolymer syringe (COC). It has a glass-like appearance but is break-resistant and lightweight. COC syringes are suitable for a variety of medications, including highly viscous drugs, and provide an extended product shelf-life. The disconnected plunger allows for easier storage.
Also, the expansion of facilities for the production of syringes is contributing to the growth of the market. For instance, in June 2022, WuXi Biologics launched the GMP operation of its new drug product facility, DP5, which is located in Wuxi, China. It is a global manufacturing facility for the production of vials and pre-filled syringes.
Thus, these aforementioned factors will collectively drive the market’s growth over the analysis period. However, the rise in the incidence of needle-stick injuries, the high cost associated with safe syringes, and the availability of alternate drug delivery methods are likely to hinder the growth of the syringe market globally.
Syringe Market Trends
Prefilled Syringes Segment is Expected Gain Acceptance Over the Forecast Period
Prefilled syringes have gained acceptance in the market as drug delivery systems designed for injectable drugs. Prefilled syringes provide the advantage of precise dosing, as the syringes are already loaded with a dose worth of the drug. They are generally preferred for the parenteral administration of various drugs, and they are used mainly for the treatment of chronic diseases such as cancer, diabetes, and several other diseases.
The COVID-19 outbreak has also led to an increased demand for prefilled syringes. For instance, in November 2020, ApiJect received approval for a USD 590 million loan from the United States International Development Finance Corporation to support the building of a United States-based facility with a surge capacity to produce up to 3 billion single-dose prefilled plastic injectors per year with no supply chain limitations. ApiJect’s new campus has 15 production lines to fill and finish vaccines and therapeutics for COVID-19.
Additionally, the approval by the regulatory authorities is also boosting the growth of the segment. For instance, in January 2021, Aurobindo Pharma Limited received final approval from the United States Food and Drug Administration to manufacture and market Naloxone HCl injection prefilled syringe 2 mg/2 ml. Also, in July 2021, Fresenius Kabi introduced Fentanyl Citrate injection, USP 50 mcg per 1 mL in its proprietary simplest ready-to-administer prefilled syringe in the United States.
Hence, owing to the aforementioned factors, the prefilled syringe segment of the market studied is expected to witness rapid growth over the forecast period.
Asia-Pacific is Expected to Grow at Healthy Rate Over the Forecast Period
The Asia-Pacific market for syringes is expected to witness healthy growth during the forecast period. Factors such as improving economic conditions, the rise in purchasing power of the people, the growth in awareness regarding the advantages of prefilled syringes, and the presence of a large patient pool suffering from various chronic diseases are expected to drive the market in the Asia-Pacific region.
The increased focus of market players on product launches also drives the market growth in the region. For instance, in July 2020, Cipla received approval for the generic version of Shire’s Firazyr (Icatibant Injectable Pre-Filled Syringe 30mg/3mL). It is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults. Additionally, in August 2021, Otsuka Pharmaceutical Co., Ltd. (Otsuka) launched AJOVY Subcutaneous Injection 225 mg Syringe (the generic name is fremanezumab) in Japan for the indication of preventive treatment of migraine in adult patients.
Moreover, due to the coronavirus outbreak, there has been a higher demand for syringes in the region. The COVID-19 pandemic has resulted in a large number of individuals being admitted to hospitals. These hospital admissions are followed by various tests using blood samples and injections of various medications to subdue the symptoms due to the virus, which is expected to further fuel the market growth.
Also, the strategic initiatives taken by the market players are expected to propel the growth of the market. For instance, in April 2021, West Pharmaceutical Services, Inc. extended its partnership with domestic Indian pharma company Venus Remedies Ltd. to deliver the NovaGuard SA Pro safety system, a single-use accessory for prefilled ISO standard 1 mL long staked-needle syringes in the Indian market.
Thus, owing to the abovementioned factors, the Asia-Pacific region is expected to project growth over the forecast period.
Syringe Market Competitor Analysis
The syringe market is highly fragmented, with the presence of a large number of local and international players. Key players adopt different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key market players are Cardinal Health, BD, Smith Medical, and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Chronic Diseases and Infectious Diseases
4.2.2 Increased Adoption of the Injectable Drugs
4.2.3 Technological Advancements in Syringes by Medical Device Companies
4.3 Market Restraints
4.3.1 Growing Cases of Needle-stick Injuries, Coupled with High Cost of Safety Syringes
4.3.2 Availability of Alternate Drug Delivery Methods
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Usage
5.1.1 Sterilizable/Reusable Syringes
5.1.2 Disposable Syringes
5.1.2.1 Conventional Syringes
5.1.2.2 Safety Syringes
5.1.2.3 Prefilled Syringes
5.2 By Application
5.2.1 Insulin Syringes
5.2.2 Botox
5.2.3 Osteoarthritis
5.2.4 Human Growth Hormone
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton Dickinson and Company.
6.1.2 B. Braun Melsungen AG
6.1.3 Gerresheimer AG
6.1.4 Hindustan Syringes & Medical Devices Limited
6.1.5 Terumo Corporation
6.1.6 Nipro Corporation
6.1.7 Schott AG
6.1.8 Cardinal Health Inc.
6.1.9 Smiths Medical
6.1.10 Johnson & Johnson
6.1.11 Baxter International Inc.
6.1.12 Pfizer Inc.
6.1.13 Teva Pharmaceuticals Industries Ltd
6.1.14 Fresenius SE & Co. KGaA
7 MARKET OPPORTUNITIES AND FUTURE TRENDS